MDxHealth SA (NASDAQ:MDXH) Given Average Recommendation of “Moderate Buy” by Brokerages

MDxHealth SA (NASDAQ:MDXH) has received an average rating of “Moderate Buy” from the six research firms that are covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $4.6250.

A number of research analysts have weighed in on MDXH shares. BTIG Research decreased their target price on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, May 14th. Lake Street Capital dropped their price target on MDxHealth from $9.00 to $5.00 and set a “buy” rating for the company in a research report on Thursday, May 14th. William Blair lowered MDxHealth from an “outperform” rating to a “market perform” rating in a research report on Thursday, May 14th. Wall Street Zen lowered MDxHealth from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of MDxHealth in a research report on Friday, March 27th.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MDXH. Intesa Sanpaolo Wealth Management purchased a new position in shares of MDxHealth during the 4th quarter worth $36,000. Lido Advisors LLC purchased a new position in shares of MDxHealth during the 3rd quarter worth $48,000. GSA Capital Partners LLP purchased a new position in shares of MDxHealth during the 3rd quarter worth $48,000. Squarepoint Ops LLC purchased a new position in shares of MDxHealth during the 4th quarter worth $51,000. Finally, Jefferies Financial Group Inc. purchased a new position in shares of MDxHealth during the 3rd quarter worth $53,000.

MDxHealth Stock Performance

NASDAQ MDXH opened at $0.41 on Friday. The business has a fifty day moving average price of $1.09 and a 200 day moving average price of $2.47. MDxHealth has a one year low of $0.40 and a one year high of $5.33. The company has a market cap of $20.32 million, a P/E ratio of -0.63 and a beta of 1.36.

MDxHealth (NASDAQ:MDXH) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.05). MDxHealth had a negative net margin of 29.90% and a negative return on equity of 1,078.01%. The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million. As a group, sell-side analysts predict that MDxHealth will post -0.6 EPS for the current fiscal year.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.